Order results by:
| Issue | Title | |
| Vol 14, No 5 (2018) | Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA | Abstract similar documents |
| Bayer Company Press Release | ||
| "... антикоагулянта ривароксабана в дозе 2,5 мг 2 р/д в сочетании с 75-100 мг ацетилсалициловой кислоты один раз в ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... Resources and methods for improving the prognosis in patients with chronic ischemic heart disease ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... atherosclerosis, as well as to the management of the high risk of ischemic events in such patients, are outlined ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... of antiplatelet therapy. The combination of rivaroxaban in a dose of 2.5 mg and standard double antiplatelet ..." | ||
| Vol 12, No 5 (2016) | The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin | Abstract similar documents |
| I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich | ||
| "... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized ..." | ||
| Vol 14, No 4 (2018) | Possibilities of Using Rivaroxaban in Elderly Patients with Atrial Fibrillation: Data from Randomized Studies and Real Clinical Practice | Abstract similar documents |
| N. M. Vorobyeva, O. N. kacheva | ||
| "... of rivaroxaban in these age groups. Rivaroxaban reduced the risk of stroke/systemic embolism by 38% and ischemic ..." | ||
| Vol 12, No 4 (2016) | Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation | Abstract similar documents |
| S. G. Kanorskii | ||
| "... In XANTUS study the safety and efficacy of factor Xa inhibitor rivaroxaban were evaluated ..." | ||
| Vol 16, No 3 (2020) | Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics? | Abstract similar documents |
| S. G. Kanorskii | ||
| "... the modern possibilities of assessing the risk of ischemic and hemorrhagic events in a stable course ..." | ||
| Vol 13, No 5 (2017) | RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE | Abstract similar documents |
| статья Редакционная | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| "... % of the population. Non-valvular AF increases the risk of ischemic stroke in 5-7 times. More than 50 ..." | ||
| Vol 15, No 3 (2019) | Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities | Abstract similar documents |
| article Editorial | ||
| "... of both coagulation and platelet). Experts noted that combination of rivaroxaban 2.5 mg BID ..." | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... and rivaroxaban). Aim. To assess the influence of apixaban use on the budget as an alternative to warfarin ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... в сравнении с варфарином, а риск коронарных событий не зависел от наличия у пациента ишемической ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... of cardiac surgery was in 27.6% of patients. All patients had >3 risk factors for ischemic stroke (CHA2DS2 ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... together data from current clinical recommendations on antiplatelet therapy in patients with ischemic ..." | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... influence both clinical and asymptomatic peripheral atherosclerotic disease on adverse ischemic events ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| "... with anticoagulants to prevent an ischemic stroke and systemic thromboembolisms. However, in case of combination AF ..." | ||
| Vol 17, No 2 (2021) | Analysis of Anticoagulant Therapy in the Elderly Patients, in Clinical Practice of Family Medicine Centers in the Kyrgyz Republic | Abstract similar documents |
| S. M. Mamatov, B. Kanat kyzy, A. O. Musakeev, N. K. Kinderbaeva, T. J. Tagaev | ||
| "... , antiplatelet agents - 196 (50.6%), no therapy - 24 (6.2%). Anticoagulant therapy in 153 patients included ..." | ||
| Vol 10, No 3 (2014) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... attractive, is rivaroxaban. ..." | ||
| Vol 11, No 6 (2015) | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD | Abstract similar documents |
| L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko | ||
| "... attractive, is rivaroxaban. ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| "... inflammation and to reveal particularities of its usage in ischemic heart disease (IHD) patients with active ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| "... of AF. CHA2DS2-VASc score was used in all patients for calculation the risk of ischemic stroke ..." | ||
| Vol 8, No 3 (2012) | RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . The alternative antithrombotic agents, including rivaroxaban presented along with the traditional drugs (acetyl ..." | ||
| Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
| M. Yu. Gilyarov | ||
| "... . Along with traditional drugs (acetylsalicylic acid, warfarin) rivaroxaban is specially considered ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... myocardial infarction (MI) and database of patients experienced angiography because of stable ischemic heart ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... . Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary ..." | ||
| Vol 18, No 1 (2022) | The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases" | Abstract similar documents |
| M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok | ||
| "... Aim. To assess the outcomes of combination therapy with rivaroxaban and acetylsalicylic acid (ASA ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... with arterial hypertension (HT) and ischemic heart disease (IHD), and the possibility of the correction ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... for assessing the effectiveness of antiplatelet therapy in patients with ischemic heart disease. ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... ,8 y.o.) with ischemic heart disease (IHD) (which was presented by angina pectoris, class I-III ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| "... of antithrombotic therapy in the early (hospital) and the delayed periods (up to 1 year after acute ischemic events ..." | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... in patients with proven stable ischemic heart disease (IHD) before admission, during inpatient stay ..." | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... The review presents recent data on the usage of platelet functional tests in patients with ischemic ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... the direct oral anticoagulant rivaroxaban showed a tendency to reduce the risk of thromboembolism by 20 ..." | ||
| Vol 17, No 2 (2021) | The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation | Abstract similar documents |
| I. A. Zolotovskaya, V. D. Sabanova, I. L. Davydkin | ||
| "... of this strategy is the control of comorbidities and risk factors for cardiovascular diseases. To date, rivaroxaban ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most ..." | ||
| Vol 15, No 4 (2019) | Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... results demonstrate a favorable efficiency and safety profile of rivaroxaban in comparison with warfarin ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most favorable ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... , case-controlled, single-center study, which included 94 consecutive patients with documented ischemic ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet ..." | ||
| Vol 12, No 1 (2016) | Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of rivaroxaban together ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF ..." | ||
| Vol 20, No 2 (2024) | Characteristics of the Russian population of patients with coronary artery disease or peripheral artery disease in the XATOA registry | Abstract similar documents |
| V. S. Arakelyan, A. D. Erlikh, N. Sh. Amirov, E. Dubar, K. Vogtlaender, S. Debus | ||
| "... inhibition therapy with rivaroxaban 2,5 mg twice a day and low-dose acetylsalicylic acid (ASA) daily were ..." | ||
| Vol 14, No 5 (2018) | Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, M. A. Gabitova, L. N. Uddin | ||
| "... ) on rivaroxaban therapy are presented. Good efficacy and safety of full and reduced doses of rivaroxaban were ..." | ||
| Vol 1, No 1 (2005) | ACE INHIBITORS IN PATIENTS WITH ISCHEMIC HEART DISEASE WITHOUT HEART FAILURE: CLASS EFFECTS AND EFFICACY OF ITS REPRESENTATIVES | Abstract similar documents |
| Y. A. Karpov | ||
| "... of the role of ACE inhibitors in treatment of patients with stable form of ischemic heart disease without ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as acetylsalicylic acid ..." | ||
| Vol 17, No 2 (2021) | Adherence to Medical Treatment in Elderly Patients with Coronary Artery Disease in the Settings of Primary Outpatient Care | Abstract PDF (Eng) similar documents |
| S. K. Zyryanov, S. B. Fitilev, A. V. Vozzhaev, I. I. Shkrebneva, N. N. Shindryaeva, D. A. Klyuev, L. N. Stepanyan, A. M. Lutsenko, A. T. Tsai, A. A. Danilova | ||
| "... that improve prognosis were also prescribed comparably: antiplatelets (66.4% vs 61.9%; p>0.05), anticoagulants ..." | ||
| Vol 9, No 6 (2013) | DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE | Abstract PDF (Eng) similar documents |
| S. A. Shalnova, A. D. Deev, S. A. Boytsov | ||
| "... At the present time ischemic heart disease (IHD) continues to be the leading cause ..." | ||
| Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
| "... characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic ..." | ||
| Vol 12, No 3 (2016) | THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT | Abstract PDF (Eng) similar documents |
| S. R. Gilyarevskiy | ||
| "... the validity of monotherapy tactics with rivaroxaban in patients with VTE. The results of this study ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... patients (50 patients received apixaban and 42 – rivaroxaban) with non-valvular atrial fibrillation ..." | ||
| Vol 19, No 1 (2023) | Value of Safety of Anticoagulant Therapy in Elderly Patient with Atrial Fibrillation and High Risk of Bleeding | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... safety of rivaroxaban in patients over 80 years of age, with a high risk of bleeding ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..." | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... was previously demonstrated in ARISTOTLE trial. On the contrary, rivaroxaban was associated with the most ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... of genotype on rivaroxaban pharmacokinetics in the study involving the carriers of ABCB1 gene rs2032582 and rs ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 2 (2020) | Specificities of Approaches to Anticoagulant Therapy in Comorbid Patients with Atrial Fibrillation, Diabetes Mellitus and Impaired Kidney Function | Abstract similar documents |
| N. V. Drobotya, E. Sh. Guseynova, A. A. Pirozhenko | ||
| "... . Rivaroxaban may meet these requirements; its use has significant advantage in high adherence to therapy. ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 14, No 6 (2018) | The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release . | Abstract PDF (Eng) similar documents |
| artilce Editorial | ||
| Vol 9, No 2 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| "... of cardiovascular complications (antiplatelets, β-blockers, ACE inhibitors, statins) were not often prescribed ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| "... platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease ..." | ||
| Vol 17, No 3 (2021) | An Integrated Approach to the Management of a Multimorbid Patient with Atrial Fibrillation from the Standpoint of Modern Guidelines: Rivaroxaban is in Focus | Abstract similar documents |
| V. N. Larina, O. Sh. Oynotkinova, A. P. Majorova, G. A. Egiazarian, T. Yu. Demidova | ||
| "... of the concept of comprehensive patient protection. Rivaroxaban is considered by the authors of the article ..." | ||
| Vol 13, No 2 (2017) | RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY | Abstract similar documents |
| . Editorial | ||
| "... эффективность и безопасность ривароксабана в дозах 20 мг 1 р/д*, 10 мг 1 р/д и ацетилсалициловой кислоты в дозе ..." | ||
| Vol 15, No 6 (2019) | Possibilities of PRECISE-DAPT Score for Risk Prediction of Ischemic and Hemorrhagic Events in ST-Elevated Myocardial Infarction (According to the Data of the Registry Study in Kemerovo) | Abstract similar documents |
| D. Yu. Sedykh, V. V. Kashtalap, R. M. Velieva, O. L. Barbarash | ||
| "... , the peculiarities of double antiplatelet therapy (DAPT) prescription as well the incidence of ischemic ..." | ||
| Vol 14, No 6 (2018) | Anticoagulant Therapy in “Fragile” Elderly Patients: Current State of the Problem | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... showed that only therapy with rivaroxaban (out of three direct oral anticoagulants) compared ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... . The authors analyzed a large database of patients with atrial fibrillation and concluded that rivaroxaban ..." | ||
| Vol 10, No 2 (2014) | RIVAROXABAN IN PATIENTS STABILIZED AFTER A ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE ATLAS ACS-2–TIMI-51 TRIAL | Abstract similar documents |
| J. L. Mega, E. Braunwald, S. A. Murphy, A. N. Plotnikov, P. Burton, R. G. Kiss, A. Parkhomenko, M. Tendera, P. Widimsky, C. M. Gibson | ||
| "... Цель. Представлен анализ лечения ривароксабаном в заранее определенной подгруппе больных инфарктом ..." | ||
| Vol 11, No 5 (2015) | New data of the real clinical practice confirms low incidence of major bleeding when using rivaroxaban in patients with non-valvular atrial fibrillation | Abstract similar documents |
| article Editorial | ||
| "... rivaroxaban in patients with non-valvular atrial fibrillation ..." | ||
| Vol 9, No 4 (2013) | STATINS IN PREVENTION OF ISCHEMIC STROKE | Abstract similar documents |
| A. V. Susekov, A. B. Blohin, Z. G. Luginova, E. J. Soloveva, N. V. Maltseva, O. E. Tarasova, V. V. Kuharchuk | ||
| "... The evidence base of statin therapy in primary and secondary prevention of ischemic stroke ..." | ||
| Vol 8, No 1 (2012) | RANOLAZINE IN ISCHEMIC HEART DISEASE | Abstract similar documents |
| V. P. Lupanov | ||
| "... ) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 ..." | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... for DFS and rivaroxaban (group 1; n=24) or combination therapy for DFS and dabigatran (group 2; n=22 ..." | ||
| Vol 13, No 5 (2017) | ADHERENCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION – THE WAY TO SOLVE THE PROBLEM OF EFFICACY AND SAFETY OF TREATMENT | Abstract similar documents |
| S. G. Kanorskii | ||
| "... . Rivaroxaban can be given in fixed doses without routine coagulation control, and phase III studies and actual ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... on rivaroxaban has changed — instead of "use with caution", as stated in the previous document from 2019 ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES | Abstract similar documents |
| A. N. Meshkov | ||
| "... of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors ..." | ||
| Vol 15, No 5 (2019) | Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, S. P. Korchagina, T. M. Ostroumova, M. S. Chernyaeva, A. A. Kirichenko | ||
| "... strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called ..." | ||
| Vol 13, No 3 (2017) | ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION | Abstract similar documents |
| F. I. Belyalov | ||
| "... The ischemic heart disease (IHD) with comorbid kidney dysfunction has more severe course and worse ..." | ||
| 1 - 100 of 604 Items | 1 2 3 4 5 6 7 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
.jpg)
